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Abstract
Prednisolone and other glucocorticoids (GCs) are potent anti-inflammatory drugs, but chronic use is hampered by
metabolic side effects. Therefore, there is an urgent medical need for improved GCs that are as effective as classical GCs but
have a better safety profile. A well-established model to assess anti-inflammatory efficacy is the chronic collagen-induced
arthritis (CIA) model in mice, a model with features resembling rheumatoid arthritis. Models to quantify undesired effects of
glucocorticoids on glucose kinetics are less well-established. Recently, we have described a model to quantify basal blood
glucose kinetics using stably-labeled glucose. In the present study, we have integrated this blood glucose kinetic model in
the CIA model to enable quantification of both efficacy and adverse effects in one animal model. Arthritis scores were
decreased after treatment with prednisolone, confirming the anti-inflammatory properties of GCs. Both inflammation and
prednisolone induced insulin resistance as insulin secretion was strongly increased whereas blood glucose concentrations
and hepatic glucose production were only slightly decreased. This insulin resistance did not directly resulted in
hyperglycemia, indicating a highly adaptive compensatory mechanism in these mice. In conclusion, this ‘all-in-one’ model
allows for studying effects of (novel) GC compounds on the development of arthritis and glucose kinetics in a single animal.
This integrative model provides a valuable tool for investigating (drug-induced) metabolic dysregulation in an inflammatory
setting.
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Introduction
Prednisolone and other glucocorticoids (GCs) are very potent
immunosuppressive and anti-inflammatory compounds that are
among the top 10 most prescribed drugs [1]. Exogenous GCs are
used in daily clinical practice to treat (chronic) inflammatory,
autoimmune and allergic disorders, to attenuate organ rejection
after transplantation, to treat brain edema, shock and various
blood cancers [2]. Most of the effects of GCs are mediated through
binding of GCs to the glucocorticoid receptor (GR), which is found
in almost all human tissues.
Although very effective in reducing inflammation, prolonged
treatment at medium or high dose of GCs is hampered by a wide
range of metabolic side effects such as derangements of glucose
metabolism, induction of insulin-resistance, beta-cell dysfunction,
hyperlipidemia, fat redistribution and central obesity that are all
strongly associated with elevated risk for cardiovascular disease
and type 2 Diabetes mellitus in humans [3–5]. The mechanisms
of action underlying these metabolic side effects are largely
unknown.
Seen this wide range of GC-induced side effects, there is a
high medical need for improved anti-inflammatory drugs that
are as effective as classical GCs but show less metabolic side
effects. This type of experimental compounds are often referred
to as selective GR modulators (SGRMs) [4]. Given the
complexity of glucocorticoid actions, the use of animal models
is required to investigate these mechanisms and several animal
models have been applied to study the efficacy and/or
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metabolic side effects of new pharmaceutical compounds in vivo
[6,7]. Preclinical efficacy of experimental GCs is often measured
in collagen-induced arthritis (CIA) mice, a chronic inflamma-
tory model with features resembling rheumatoid arthritis (RA)
[8,9]. Arthritis can be induced in susceptible strains of mice by
immunization with type II collagen, the major component of
articular cartilage, and has histopathologic and serological
features in common with RA [10,11]. Regarding in vivo
investigation of (compound-induced) metabolic dysregulation,
such as insulin resistance, a number of methods have been
developed to measure glucose and insulin kinetics, of which the
hyperinsulinemic euglycemic clamp (HIEC) is considered as the
‘gold standard’. With respect to mice studies, the HIEC is
difficult to use for longitudinal studies, since it can only be
performed once in a single animal [12]. In addition, arthritic
mice in the CIA model are severely ill, with highly inflamed
joints and therefore these mice can not be subjected to the
invasive HIEC protocol. To overcome these drawbacks, a new
method was developed in which stably-labeled glucose (D-
[6,6-2H2]-glucose) was used in combination with a single-pool,
first order kinetic model to determine blood glucose kinetics
[13]. This model is especially of interest for longitudinal studies,
due to the ability of repeated measurements.
Currently, an animal model to study both efficacy and
glucocorticoid-induced metabolic side effects in a chronic inflam-
matory setting is not available. Therefore, the aim of the present
study is to develop a chronic inflammatory model which can be
used to investigate both efficacy andmetabolic safety of GCs in the
same animal at the same time. To do so, we have integrated the
newly developed blood glucose kinetics model into the CIA mice
model.
Table 1. The formulas used to calculate the concentration vs. time curves and the kinetic parameters in a first order absorption
process in an one-compartment model.
Eq. 1 Tracer Concentration at time point t Ct~Mt| glc½ t
Eq. 2 Single-pool first-order kinetics Ct~C
el
0 e
{kel t{Cab0 e
{kabt
Eq. 3 Bioavailability
F~1{
Cab0 |k
el
kab|Cel0
 !
Eq. 4 Area under the curve
AUC~
Cel0
kel
{
Cab0
kab
Eq. 5 Metabolic clearance rate
MCR~
F|D
AUC
Eq. 6 Apparent volume of distribution
V~
MCR
kel
Eq. 7 Turnover rate Ra~MCR|BG
Eq. 8 Pool size
A~
Ra
kel
Ct, D-[6,6-
2H]-glucose concentration at time point t; Mt, fractional contribution of D-[6,6-
2H]-glucose at time point t; [glc]t, blood glucose concentration at time point t.
C(0)ab, initial concentration of D-[6,6-2H]-glucose determined by extrapolation of the absorption period; C(0)el, initial concentration of D-[6,6-2H]-glucose determined by
extrapolation of the elimination period; kab, absorption rate constant; kel, absorption rate constant. D, dose D-[6,6-2H]-glucose administrated; BG, average blood glucose
concentration during the test; Ra = EGP.
doi:10.1371/journal.pone.0098684.t001
Figure 1. Arthritis development. Arthritis development in mice subjected to blood glucose kinetics three times and in mice in which no
experiments were performed. (A) AUC of the overall arthritis score, corrected for base line, after 21 days. (B) X-ray analysis to assess bone destruction.
Results are presented as mean 6 SEM (n= 20). No significant differences between the two groups was observed. NS = not significant.
doi:10.1371/journal.pone.0098684.g001
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To validate this model and to investigate the mechanisms
involved in GC-induced metabolic dysfunction in a chronic
inflammatory setting, we performed two consecutive CIA exper-
iments. First, we assessed the effects of several doses of
prednisolone (0, 1.5, 10 and 30 mg/kg/day) on efficacy and
metabolic safety after 0, 7 and 21 days of treatment. Next, in order
to distinguish between direct effects of prednisolone and indirect
effects on glucose kinetics resulting from its anti-inflammatory
efficacy, we compared effects of prednisolone to those of ORG
37663. This compound is a steroid which has previously been
described to be effective for the treatment of arthritis in CIA mice,
but mediates its effect through the estrogen receptor alpha (ERa)
instead of the GR (6). Comparing the results from the
prednisolone-treated subgroup to the subgroup treated with the
anti-inflammatory compound ORG 37663 allowed us to distin-
guish between direct effects of prednisolone on glucose and insulin
kinetics and indirect effects induced by the anti-inflammatory
properties of prednisolone.
The results from this study reveal that it was possible to
measure both efficacy and metabolic side effects of prednisolone
in one experimental set-up. Arthritis scores were dose-depen-
dently decreased in arthritic mice after treatment with both
prednisolone and ORG 37663. Concerning effects on glucose
metabolism, there was a decrease in insulin sensitivity in both
arthritic and non-arthritic control mice after treatment with
prednisolone for three weeks, while ORG 37663 unexpectedly
increased insulin sensitivity in both groups. These prednisolone-
mediated effects on insulin sensitivity were mainly reflected by an
increased insulin secretion.
Overall, the integration of these two models provides a valuable
tool for studying both the efficacy and metabolic side-effects of
experimental glucocorticoids at the same time in one model.
Methods
Animals
All experiments were approved by the Animal Welfare
Committee of MSD Oss, The Netherlands. Male DBA1/J mice
were obtained from Bomholtgard (Ry, Denmark). Animals were
housed and maintained at 23uC with ad libitum access to water
and food in a 12 hour-12 hour light-dark cycle (lights on 6 am-6
pm).
Therapeutic murine collagen-induced arthritis
The murine CIA model was performed as previously described
[14]. In brief, DBA1/J mice were immunized at the base of the tail
at the age of eight weeks with 200 mg bovine type II collagen in
complete Freud’s adjuvant enriched with 2 mg/ml M. tuberculosis
(H37Ra). Three weeks after immunization the animals were
boosted with an intraperitoneal injection of 200 mg collagen type
II, dissolved in saline. Earlier experiments have taught us that,
after immunization, mice will drop-out due to an early aggressive
arthritis or fail to develop arthritis. About 60–70% of the mice
develop the necessary arthritis. Therefore, the total amount of
mice that are immunized and boosted for the experiment is 40%
above the actual number of mice needed for the experiment. The
clinical severity of arthritis (arthritis score) was graded per
inflamed digit (a scale of 0 to 2 for each paw). Mice were scored
on alternative days, resulting in mean scores with an overall
maximum of 8 per animal. To assess the effects of treatment, the
area under curve (AUC) of the mean arthritis of each animal with
baseline correction (subtracting baseline AUC of arthritis score on
day 0) was used. After disease onset, animals with an arthritis score
ranging from 2 to 4 were divided into separate groups of 12 mice
so that the mean arthritis score of all experimental groups was
comparable at the start of the treatment (day 0). Mice were
considered to have arthritis when significant changes in redness
and/or swelling were noted in the digits or in other parts of the
paws.
Treatment and experimental regimes
For the first experiment, a total of 40 arthritic animals were
divided into an experimental and a control group of 20 mice each.
Both groups were orally treated once a day for 21 days with
placebo (0.5% gelatin and 5% mannitol in water) and arthritis
development was monitored. In the experimental group (n= 20)
mice were subjected to a blood glucose kinetics test three times (on
day 0, 7 and 21) while mice in the control group were not
subjected to the blood glucose kinetics tests.
For the second experiment, arthritic animals were treated orally
once a day for 21 days with either 1.5, 10 or 30 mg/kg
prednisolone in vehicle (0.5% gelatin and 5% mannitol in water)
or vehicle alone as placebo. In total, 48 arthritic mice (12 per
treatment group) were included. For non-arthritic control groups,
mice were mock immunized with saline at the base of the tail at
the age of eight weeks and three weeks later mock boosted with
saline. Mice were further treated according the same experimental
protocol and handled exactly the same as the mice that developed
arthritis. In this study, these mice are referred to as non-arthritic
control mice.
For the third experiment, arthritic mice were treated orally once
a day for 21 days either with prednisolone (10 mg/kg) or ORG
37663 (12 mg/kg) in vehicle (0.5% gelatin and 5% mannitol in
water) or vehicle alone as placebo. The dose of 12 mg/kg/day for
ORG 37663 was selected because this dose is comparable to a
dose of 10 mg/kg/day prednisolone regarding efficacy [6]. In total,
36 arthritic mice (12 per treatment group) and 36 non-arthritic
control mice, like described above, were included in this
consecutive experiment.
All experimental treatments were conducted in a blinded
fashion. At the end of the experiment, serum samples and hind
knees and paws were obtained. Hind knees and paws were
evaluated using X-ray analysis to assess bone destruction [15]. X-
ray photographs were examined with a Faxitron X-ray MX-20
(0.02 mm resolution) and bone destruction was scored on a scale
from 0 to 5 ranging from no damage to complete destruction [16].
Blood glucose kinetics
The fasted blood glucose kinetic test was performed three times;
at day 0 (before treatment, but after disease onset) and after 7 and
21 days of treatment. For each experiment, mice were fasted for
9 hours overnight (11.00 pm–8.00 am), body weights were
measured and mice were injected intraperitoneally with a small
volume of 2.0 mg D-[6,6-2H2]glucose in 0.20 ml by intraperito-
neal injection (,450 mmol/kg BW) which did not cause changes
in blood glucose and plasma insulin concentrations. Before and at
10, 20, 30, 40, 50, 60, 75 and 90 minutes after D-[6,6-2H2]-
glucose administration, blood glucose concentrations were mea-
sured in a blood drop collected by tail tip bleeding using a
glucocard X-meter (A. Menarini Diagnostics; Valkenswaard; The
Netherlands). At the same time points, a small blood spot was
taken on filter paper (FT-2-460-210297, Sartorius, Goettingen,
Germany) and stored at room temperature until further analysis of
D-[6,6-2H2]-glucose label distribution. After the last test (day 21) a
blood sample (15 ml) was taken by tail tip bleeding for C-peptide
measurements.
Glucose Kinetics in CIA Mice
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Figure 2. Effects of prednisolone on bodyweight, thymus weight and arthritis development after 21 days of treatment. (A)
Bodyweight (B) thymus weight (C) AUC of the overall arthritis score (D) X-ray analysis to assess bone destruction. Results are represented as means6
SD for bodyweight and thymus weight and as mean 6SEM for AUC arthritis score and X-ray score and are outlined for each experimental group
(n = 12). * Significant difference p#0.05, ** significant difference p#0.01, *** significant difference p#0.001, NS = not significant.
doi:10.1371/journal.pone.0098684.g002
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Measurements of mass isotopomer distribution by
GC-MS
Whole body glucose turnover and clearance were calculated by
kinetic analysis from the wash-out of injected D-[6,6-2H2]-glucose
from circulation for which blood spots on filter paper were taken.
Extraction of glucose from filter paper, derivatization of the
extracted compounds and gas chromatography-mass spectrometry
(GC-MS) measurements of blood glucose was performed as
previously described by Van Dijk and colleagues [17]. In short,
a disk was punched out of the blood spots, glucose was extracted
from the disk by incubation in ethanol/water (10:1 v/v) and
glucose was derivatized to its pentaacetate-ester. Samples were
analyzed by GC-MS with positive ion chemical ionization with
ammonia. The fractional isotopomer distribution measured by
GC-MS (m0-m6) was corrected for the fractional distribution due
to natural abundance of 13C by multiple linear regression as
described by Lee et al. [18] to obtain the excess fractional
distribution of mass isotopomers (M0-M6) due to dilution of
infused labeled compounds.
Calculation of blood glucose kinetics
For calculating the blood glucose kinetics parameters EGP
(Endogenous Glucose Production) and MCR (Metabolic Clear-
ance Rate), a single-pool, first-order kinetic model was assumed
[19–21]. The excess fractional distribution of mass isotopomers
(M2) was used to calculate the first order absorption process in an
one-compartment model using SAAM-II software (version 1.2.1;
SAAM Institute, University of Washington, Seattle, WA, USA)
[13]. The formulas used to calculate the concentration vs. time
curves and the kinetic parameters are outlined in Table 1.
C-peptide measurements
In this study C-peptide concentrations as a marker for insulin
production, since the half-life of C-peptide is longer than that of
insulin. Thereby, by measuring C-peptide we can focus on de
novo synthesis of insulin and not just circulating insulin that might
also be released/taken up by cells. Peripheral blood samples
obtained after each experiment were centrifuged and the retrieved
serum samples were stored at 220uC until analyzed. C-peptide
concentrations were measured using a commercially available
ELISA kit (mouse C-peptide ELISA; Alpco immunoassays, Salem,
NH, USA).
Calculation of HOMA-IR
The Homeostasis Model Assessment for Insulin Resistance
(HOMA-IR) combines fasting glucose and insulin concentrations
to calculate insulin resistance [22]. Besides using insulin, it is also
possible to calculate the HOMA-IR using C-peptide concentra-
tions [23]. The HOMA-IR expresses changes in insulin sensitivity
and b-cell function relative to a population in which these
parameters are considered to be normal. However, although the
HOMA-IR has been used for mice studies previously, it was
developed based upon human values. Therefore we adjusted the
HOMA-IR for mice in which the healthy mice, treated with
placebo, had an insulin resistance (IR) of 1 (no insulin resistance).
This group is used as the reference group. The reference value can
be calculated from median blood glucose concentration (6.6 mM)
during the blood glucose kinetics protocol and the mean plasma C-
peptide concentration (221 pM) at the end of the test. For this
study, the value was 1459. In this manuscript, the HOMA-IR was
therefore calculated as:
HOMA-IR~
½Glu1½C-peptide
1459
In which [Glu] is the blood glucose concentration in mM and
[C-peptide] is the C-peptide plasma concentration in pM. An
HOMA-IR .1 indicates induction of insulin resistance and an
HOMA-IR ,1 indicates improved insulin sensitivity.
Insulin tolerance test
For the insulin tolerance test, mice were fasted for 4 hours
before i.p. injection with insulin (0,75 U/kg bodyweight). Blood
samples were taken by tail-cut at baseline and after 15, 30, 45, 60,
90 and 120 minutes of insulin administration. Blood glucose
concentration were measured with a blood glucose meter (Accu-
Chek Avia; Roche Diagnostics, Almere, The Netherlands).
Statistical analysis
All data are represented as mean 6 SD except for the arthritis
data which, is represented as mean 6 SEM. Data were analyzed
using, where appropriate, the Student’s t-test, ANOVA or 2-way
ANOVA followed by the Tukey post hoc test (SPSS, Chicago, IL,
USA). A p-value ,0.05 was considered significant.
Results
The blood glucose kinetics test does not interfere with
arthritis development
Before reliable statements could be made regarding predniso-
lone-induced effects on arthritis development and glucose kinetics
in mice, we wanted to confirm that the blood glucose kinetics
protocol itself did not influence arthritis development. Therefore,
we first investigated if performing this protocol three times in
arthritic mice would affect arthritis development. Figure 1 shows
that a triple blood glucose kinetic test in three weeks time did not
affect AUC of arthritis scores and X-ray scores in the CIA mouse
model.
Assessing the effects of both arthritis development and
prednisolone treatment on glucose kinetics
Blood glucose kinetics was used to assess both arthritis-induced
and prednisolone-induced metabolic dysfunction and was per-
formed three times: at day 0 (before prednisolone treatment) and
after 7 and 21 days of treatment. Before treatment, bodyweights
were significantly lower in arthritic mice when compared to non-
arthritic mice (p,0.0001) (Table 2). This decrease in bodyweight
is caused by the active inflammatory state of these arthritic mice as
was previously reported [24]. Even though arthritic mice have
lower bodyweights compared to control mice, treatment with
several doses of prednisolone for 21 days did not have any effect on
bodyweight in both groups compared to vehicle treated mice
(Table 2 and Fig. 2A).
Prednisolone treatment induced apoptosis of thymocytes,
thereby severely reducing thymus weight dose-dependently [25].
No differences in thymus weight were observed between arthritic
and non-arthritic mice. Treatment with 1.5, 10 or 30 mg/kg
prednisolone per day significantly reduced thymus weight in a
dose-dependent manner respectively with 68%, 80% and 89%
(p,0.0001) in the non-arthritic control group and with 70%, 81%
and 85% (p,0.0001) in the arthritic group (Fig. 2B). These
reductions are indicative for sufficient prednisolone exposure in
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these treatment groups. No differences in thymus weight reduction
between arthritic and non-arthritic mice was observed.
To confirm the anti-arthritic properties of prednisolone,
arthritic mice were monitored for arthritis score and X-ray score.
Prednisolone dose-dependently reduced disease severity since a
significant reduction of the AUC arthritis score covering the entire
treatment period was observed (p,0.0001) (Fig. 2C). X-ray
analysis of the arthritic joints indicate severe cartilage and bone
destruction in the placebo-treated arthritic animals. In line with
previous results [6], prednisolone significantly reduced the rate of
cartilage and bone destruction in a dose-dependent manner
(p = 0.0029) (Fig. 2D). As expected, the non-arthritic control mice
that were mock immunized with saline and three weeks later mock
boosted with saline, did not develop arthritis.
No differences were observed in blood glucose concentrations
between arthritic and non-arthritic mice before treatment
(Table 2), and after 21 days placebo treatment (p = 0.1). (Fig. 3A).
A minimal but significant decrease in blood glucose concentrations
was observed in non-arthritic mice after treatment with several
doses of prednisolone for three weeks (p = 0.0064) (Fig. 3A). Also a
slightly but significant decrease in blood glucose concentrations
was observed in arthritic mice after treatment with several doses of
prednisolone (p = 0.0012) (Fig. 3A).
The glucose kinetics parameters MCR (Metabolic Clearance
Rate) and EGP (Endogenous Glucose Production) were calculated
by modeling the wash-out of injected D-[6,6-2H2]-glucose. MCR
was increased in arthritic mice when compared to non-arthritic
before treatment started (p,0.0001) (Table 2). Prednisolone did
not affect MCR in both non-arthritic or arthritic mice (Fig 3B).
Interestingly, even though no effects were seen upon three weeks
of prednisolone treatment between the groups, MCR is lowered in
the arthritic group over time. For the non-arthritic group, MCR is
increased at day 7 but decreased at day 21 when compared
baseline (Table 2 and Fig. 3B)
Before treatment started the EGP in arthritic mice was
significantly higher than in non-arthritic mice (p,0.0001), but
decreased after 21 days of placebo treatment (Table 2), leveling
the difference between placebo-treated arthritic and placebo-
treated non-arthritic mice after 21 days of treatment (p = 0.2)
(Table 2 and Fig. 3C). Prednisolone treatment for 21 days
significantly decreased EGP in both non-arthritic (p = 0.006) and
arthritic mice (p = 0.002) (Fig. 3C).
Surprisingly, after three weeks of treatment, plasma C-peptide
concentrations of placebo treated arthritic mice were significant
lower than those of placebo-treated non-arthritic mice
(p = 0.0006). C-peptide concentrations were strongly increased in
a dose-dependent manner by prednisolone in both non-arthritic
(p,0.0001) and arthritic mice (p,0.0001) implying increased
insulin production (Fig. 3D).
From the fasting blood glucose and C-peptide concentrations,
the HOMA-IR was calculated to evaluate insulin resistance.
Remarkably, the HOMA-IR showed that placebo-treated arthritic
mice are 2.4 times more insulin sensitive than placebo-treated
non-arthritic animals (p-value = 0.0007) (Fig. 3E). According to
the HOMA-IR data, prednisolone treatment significantly reduced
insulin sensitivity in a dose-dependent manner in both non-
arthritic (p = 0.028) and arthritic mice (p = 0.0001 after correction
for differences in arthritis scores between the groups). After
treatment with prednisolone (30 mg/kg/d) for 21 days, both
groups were equally sensitive to insulin (Fig. 3E).
Validating the blood glucose kinetics results by using the
insulin tolerance test.
As described above, results from the blood glucose kinetic model
showed that prednisolone treatment significantly reduced insulin
sensitivity in both non-arthritic and arthritic mice. To validate
these results, we repeated the experiment and assessed insulin
resistance by the use of a insulin tolerance test (ITT). Both non-
arthritic and arthritic mice were treated either with prednisolone
(30 mg/kg/day) in vehicle or with vehicle alone for 21 days. After
treatment, an ITT was performed. Prednisolone reduced disease
severity as shown by a significant reduction of the AUC arthritis
score (p,0.0001) (Fig. 4A). Fasting glucoses were not significant
different between groups (Fig. 4B). Results from the ITT
demonstrated that non-arthritic mice treated with vehicle were
more insulin sensitive than non-arthritic mice treated with
prednisolone (Fig. 4C). The area under the curve showed that
differences between prednisolone- and vehicle treated animals was
significant (p = 0.012) (Fig. 4D). In arthritic animals, a clear trend
is visible suggesting that vehicle-treated mice are more insulin
sensitive than prednisolone-treated mice (Fig. 4E). However, the
AUC shows that differences are not significant (Fig. 4F). Taken
together, data from the glucose kinetics test and the ITT showed
that prednisolone treatment most likely reduces insulin sensitivity
in both non-arthritic and arthritic mice.
Assessing the effects of ORG 37663 treatment on glucose
kinetics
To distinguish between the direct effect of prednisolone on
metabolic processes versus indirect effects on metabolism via the
suppressed inflammatory condition by prednisolone, we per-
formed an experiment in which arthritic and non-arthritic mice
were treated with prednisolone or ORG 37663. The latter
compound is a steroid that was previously shown to have anti-
inflammatory properties and effectively reduces arthritis in the
CIA model. ORG 37663 mediates its effects through a mechanism
that is independent of GR binding [6]. Therefore, ORG 37663
was used in a head-to-head comparison to prednisolone in one
experiment to study to what extent effects of prednisolone on
glucose kinetics are due to its anti-inflammatory properties or due
to a direct effect through GR on metabolic pathways.
Similar to the previous experiment, bodyweights before
treatment were significantly lower in arthritic mice compared to
non-arthritic mice (p = 0.0001) (Table 3). Non-arthritic mice were
found to have significant lower bodyweights after treatment with
ORG 37663 but not after treatment with prednisolone (Fig. 5A).
In the non-arthritic control group, treatment with 10 mg/kg
prednisolone or 12 mg/kg ORG 37663 per day reduced thymus
weight respectively with 84% (P,0.0001) and 78% (P,0.0001)
(Fig. 5B). In the arthritic group thymus weight was reduced with
86% (P,0.0001) and 76% (P,0.0001), again indicative for
sufficient compound exposure. In arthritic mice, both arthritic
score and X-ray score were significantly decreased (P,0.0001 and
p= 0.0279 respectively) after treatment with either prednisolone or
ORG 37663 (Fig. 5C-D).
Figure 3. Effects of prednisolone on glucose kinetics after 21 days of treatment. (A) Blood glucose concentrations (B) MCR (C) EGP levels
MCR (D) C-peptide concentrations (E) C-peptide HOMA-IR. Results represent means 6 SD and are outlined for each experimental group (n = 12). *
Significant difference p#0.05, ** significant difference p#0.01, *** significant difference p#0.001, #significant difference (p#0.05) when compared to
the placebo-treated non-arthritic mice, NS = not significant.
doi:10.1371/journal.pone.0098684.g003
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Arthritic mice showed slight but significant lower blood glucose
concentrations after ORG 37663 treatment in comparison to
placebo treatment (p = 0.036). In both the non-arthritic and
arthritic groups of mice, no effect of prednisolone on blood glucose
concentrations was detected (Fig. 6A). Non-arthritic mice treated
with prednisolone or ORG 37663 both had a significant lower
MCR compared to placebo treated mice (p,0.0001), while this
effect was not observed in the arthritic mice after treatment
(Fig. 6B). This is probably caused by the fact that MCR was
already decreased in arthritic mice after 21 days of treatment with
placebo compared to non-arthritic mice treated with placebo (p,
0.0001). The same effect was observed for EGP: in non-arthritic
mice the EGP levels decreased by prednisolone (p = 0.0006) or
ORG 37663 treatment (p = 0.036) (Fig.6C) and a same trend was
visible in arthritic mice, but due to the fact that the placebo-treated
arthritic mice already showed some neutralization of the increased
EGP levels, the effects of prednisolone and ORG 37663 on EGP
in these mice was less obvious (as was seen in the previous
experiment).
As was observed in the prednisolone dose-response experiment,
C-peptide concentrations from arthritic mice treated with placebo
were significant lower compared to the non-arthritic mice treated
with placebo after three weeks of treatment (p-value = 0.0047)
(Fig. 6D). The ORG 37663 compound caused a decrease in C-
peptide concentrations in both non-arthritic (p,0.0001) and
arthritic mice (p,0.0001) when compared to prednisolone
(Fig. 6D). As a consequence of the low C-peptide concentrations
after treatment with ORG 37663, both arthritic (p = 0.0022) and
non-arthritic mice (p = 0.0002) showed a tremendous increase in
insulin sensitivity as calculated by the HOMA-IR (Fig. 6E). These
data indicate that treatment with ORG 37663 improved insulin
sensitivity in mice compared to prednisolone-treated mice.
Discussion
There is an urgent need for improved GCs that are as effective
as classical GCs, but have a better safety profile. However, a
chronic in vivo inflammatory model in which (experimental) GCs
can be studied for both their effectiveness and the induction of
metabolic side effects is currently unavailable. Goal of the present
study was to develop such an in vivo inflammatory model for
efficacy and metabolic adverse effects at the same time. Therefore
we have integrated a single-pool, first order kinetic protocol to
examine blood glucose kinetics, in the well-established collagen-
induced arthritis (CIA) mice model, a chronic inflammatory model
which is often used to monitor efficacy of experimental anti-
inflammatory compounds. We were able to measure effects on
glucose kinetics without influence on arthritis development.
Importantly, this indicates that we have successfully performed
blood glucose kinetics in the CIA model enabling the quantifica-
tion of both efficacy and effects on glucose metabolism in a single
animal.
The ‘gold standard’ to investigate and quantify insulin resistance
is the hyperinsulinemic euglycemic clamp (HIEC) [26]. However,
seen from the perspective of laboratory animal welfare, performing
such clamp studies within an inflammatory mouse model such as
the CIA model is impossible. Measuring glucose kinetics by
Figure 4. Assessment of insulin sensitivity by the use of the insulin tolerance test (ITT). (A) AUC of the overall arthritis score, corrected for
base line, after 21 days. (B) Blood glucose concentrations of non-arthritic and arthritic mice treated with prednisolone or vehicle. (C) Blood glucose
values during the ITT of non-arthritic mice treated with prednisolone or vehicle. (D) ITT AUC values of non-arthritic mice treated with prednisolone or
vehicle. (E) Blood glucose values during the ITT of arthritic mice treated with prednisolone or vehicle. (F) ITT AUC values of arthritic mice treated with
prednisolone or vehicle.). * Significant difference p#0.05, *** significant difference p#0.001, NS = not significant.
doi:10.1371/journal.pone.0098684.g004
Table 3. Treatment parameters for both non-arthritic and arthritic mice treated with placebo, prednisolone (10 mg/kg) or ORG
37663 (12 mg/kg) for 21 days.
Non-arthritic
mice Arthritic mice
Placebo Prednisolone ORG 37663 Placebo Prednisolone ORG 37663
Bodyweight (g) day 0 23.561.5 23.261.0 25.062.4 20.961.3# 21.562.9 20.861.3
Bodyweight (g) day 7 24.361.6 22.661.2 23.761.6 21.462.2# 21.462.7 21.761.9
Bodyweight (g) day 21 25.161.9 22.961.2 20.561.6* 21.661.7# 22.462.9 18.761.2*
Glucose (mM) day 0 3.561.1 4.661.7 3.661.8 4.861.0 5.061.1 4.560.9
Glucose (mM) day 7 5.361.9 4.461.2 5.261.4 5.760.7 4.661.0 6.060.8
Glucose (mM) day 21 5.261.4 4.960.9 4.661.5 5.961.3 5.260.8 4.760.7*
MCR (ml/kg/min) day 0 17.869.4 18.668.3 15.6610.2 19.064.1 18.962.8 13.4610
MCR (ml/kg/min) day 7 11.665.6 14.164.9 9.866.3 17.061.9# 16.762.6 8.866.9*
MCR (ml/kg/min) day 21 16.561.8 12.061.1* 13.261.9* 12.361.4# 12.961.8 13.662.4
EGP (mmol/kg/min) day 0 71.1613.3 84.6616.1 68.5619.5 92.3625.5# 95.1621.5 89.9615.9
EGP (mmol/kg/min) day 7 72.7625.6 65.5613.2 65.969.8 94.1614.3# 74.067.7* 78.7612.2*
EGP (mmol/kg/min) day 21 84.4619.4 58.468.3* 58.6612.9* 73.7619.4 66.0610.8 63.6616.4
Both non-arthritic and arthritic mice are treated with placebo, prednisolone (10 mg/kg/day) or ORG 37663 (12 mg/kg/day) for 21 days. Each experimental group consists
of 12 mice; in total 36 non-arthritic and 36 arthritic mice were included. Values represent means 6 SD during the blood glucose kinetics test except BW, which is
represented as means 6 SD before the test.
* Significant difference (p#0.05) when compared to the placebo-treated group of that same parameter.
#Significant difference (p#0.05) when compared to the placebo-treated non-arthritic mice.
doi:10.1371/journal.pone.0098684.t003
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modeling the wash-out of ip injected D-[6,6-2H2]-glucose is
performed under fasted conditions whereas the HIEC utilizes
steady-state insulin concentrations that are supraphysiological
[13,27,28]. Thus, the wash-out of ip-injected glucose presumably
reflects a more physiological relevant situation. In addition, unlike
the HIEC the blood glucose kinetics test can be applied repeatedly
and is therefore applicable in longitudinal studies, such as the CIA
model described here.
This study showed that prednisolone decreased disease severity
and joint destruction in arthritic mice, thereby confirming the anti-
inflammatory properties of this compound. Regarding the
induction of metabolic effects, prednisolone slightly decreased
fasted glucose concentrations and EGP, but strongly increased
insulin production (as measured by the increase in C-peptide
concentrations) at the same time in both non-arthritic and arthritic
mice. This resulted in an increased HOMA-IR after prednisolone
treatment, indicating the induction of insulin resistance. To
validate these results, we repeated the experiment and measured
insulin sensitivity by the use of an ITT. Results from the ITT
showed that prednisolone induced insulin resistance in both non-
arthritic and arthritic mice, thereby confirming our previous
results obtained by the blood glucose kinetic model. Although the
ITT is a more classical model to assess insulin resistance, it is only
capable of measuring glucose metabolism in peripheral tissues.
The additive value of the applied blood glucose kinetic model, i.e.,
the injection of D-[6,6-2H2]-glucose, is that this allowed for
discrimination of the changes in glucose metabolism in peripheral
tissues and the liver since the MCR reflects peripheral glucose
metabolism and EGP reflects hepatic glucose production in fasted
conditions. To our knowledge, no animal model was previously
described which enables quantification of both anti-arthritic
efficacy and longitudinal tissue-specific metabolic adverse effects
in one animal in one chronic treatment protocol. In the field of
GCs and the search for compounds with improved efficacy/safety
profiles (SGRMs), such a model is of great value since it closely
mimics the clinical RA practice. Interestingly, our results show
that the overall effects of prednisolone on glucose kinetics were
similar in both arthritic and non-arthritic animals indicating that
the disease state in this model did not influence regulation of
glucose homeostasis.
One reason to include both non-arthritic and arthritic mice in
this study was to be able to distinguish between inflammation-
induced and GC-induced metabolic dysfunction. Our results
showed that arthritic mice produce less insulin than non-arthritic
mice after treatment with placebo. It is known that arthritic mice
have elevated circulating levels of the pro-inflammatory cytokines
TNFa and IL-1b [14]. Proinflammatory cytokines have been
shown to induce beta cell dysfunction [29]. In addition, chronic
inflammation may reduce beta cell mass by stimulating apoptosis
of beta cells [30]. Also factors related to the disease status may play
a role in the difference in C-peptide production between arthritic
and non-arthritic mice. For example, mice suffering from arthritis
eat less and have to be more efficient with energy which might
affect glucose metabolism. Nonetheless, based upon the fact that
glucose concentrations did not change, the untreated arthritic
mice in our study were still able to compensate for the
inflammation-induced reduction of insulin secretion. Both severely
arthritic mice and mice treated with a high dose of prednisolone
are able to compensate for reduced insulin secretion and reduced
insulin sensitivity respectively by keeping the MCR steady and
even reduce EGP, which indicates a highly adaptive compensatory
mechanism in both groups of mice.
Regarding GC-induced insulin resistance in mice, many
conflicting results have been reported [27,31–38]. Also the results
described in this paper show discrepancies in results when
compared to previously reported studies. For instance, we report
a minimal decrease in glucose levels after treatment with
prednisolone whereas other studies reported an increase of glucose
levels after treatment with glucocorticoids [27,31–34]. One reason
explaining (at least partly) these differences in results is that
different strains of mice were used. We used DBA1/J mice since
this strain showed to be highly susceptible for inducing collagen-
induced arthritis [39]. However, most studies use C57BL/6 mice
to investigate GC-induced insulin resistance [27,36–38,40] and
DBA1/J mice are hardly ever used in diabetic or metabolic model
systems. Other reasons for differences in results between studies
might be explained by differences in study design (e.g. fasting
conditions), administered dose, treatment duration and/or route of
administration.
In humans, GCs are well known to negatively affect glucose
metabolism. Short-term clinical trials in healthy individuals have
shown that GCs reduce hepatic and peripheral insulin sensitivity
[5] and impair beta cell function [41]. Population-based studies
showed that GC use was associated, in a cumulative dose-
dependent manner, with the incidence of diabetes [42]. However,
studies investigating the metabolic effects of GCs in RA patients
yielded conflicting results. On the one hand, in cross-sectional
studies in RA patients showed that GC exposure was related to
impaired fasting insulin sensitivity [43] and tended to predict
development of type 2 diabetes [44,45]. On the other hand, the
use of GCs by patients with chronic inflammatory conditions may
improve glucose tolerance via anti-inflammatory effects, as has
been demonstrated in a number of studies [46,47]. Our results
regarding glucose and C-peptide levels are in line with the results
reported by den Uyl and co-workers. These authors investigated
the dose-related effects of short-term GC treatment on glucose
tolerance, beta cell function and insulin sensitivity in patients with
early active RA. They showed that fasting C-peptide levels
increased significantly after treatment with prednisolone while
fasting glucose levels did not change [48]. These results regarding
C-peptide and glucose levels are also observed in our experiments,
indicating reduced insulin sensitivity. However, both the non-
arthritic and arthritic mice were, after 21 days of prednisolone
treatment, still able to compensate for their prednisolone-induced
reduction in insulin sensitivity, resulting ultimately in no change in
blood glucose concentrations. Most likely, the treatment period (3
weeks) in this combined model is too short to study a next stage in
the development of diabetes, i.e., hyperglycemia and beta-cell
dysfunction. These results, together with the results reported by
den Uyl and coworkers point to a delicate balance between the
anti-inflammatory and diabetogenic effects in which dose and
duration of GC treatment are crucial. Further studies will be
needed to challenge this.
Figure 5. Effects of ORG 37663 and prednisolone on bodyweight, thymus weight and arthritis development after 21 days of
treatment. (A) Bodyweight (B) thymus weight (C) AUC of the overall arthritis score (D) X-ray analysis to assess bone destruction. Results are
represented as means 6 SD for bodyweight and thymus weight and as mean 6SEM for AUC arthritis score and X-ray score and are outlined for each
experimental group (n = 12). * Significant difference p#0.05, ** significant difference p#0.01, *** significant difference p#0.001, #significant
difference (p#0.05) when compared to the placebo-treated non-arthritic mice, NS = not significant.
doi:10.1371/journal.pone.0098684.g005
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To be able to study to what extent the effects of prednisolone on
glucose kinetics are due to its anti-inflammatory properties or due
to a direct effect on glucose kinetics, mice were also treated with
ORG 37663, a non-GC anti-inflammatory compound, and
directly compared to prednisolone. This compound was chosen
because of its strong anti-inflammatory effects that are not
mediated through the GR. Although it is reported that this
compound lacks anti-rheumatic activity in humans [49], Dulos
and co-workers showed that treatment with ORG 37663
suppressed clinical arthritis score, reduced inflammatory infiltrates
and decreased pro-inflammatory cytokines in collagen-induced
arthritis mice [6]. Also our own data showed that the clinical
arthritis score was strongly decreased after treatment with this
compound. Therefore, we believe that this compound is suitable to
compare GR- and non-GR-mediated effects in this in-vivo model.
Treatment with ORG 37663 resulted in lower C-peptide
concentrations when compared to prednisolone treatment in both
non-arthritic and arthritic mice. This indicates that prednisolone
mediates its effects on insulin production directly and not via
indirect anti-inflammatory effects. However, the effects on glucose
kinetics (MCR) and metabolism (EGP) seem to be due to the anti-
inflammatory activity of prednisolone as treatment with another
(non-GR agonistic) anti-inflammaroy drug (ORG 37663) showed
the same effects. However, ORG 37663 also influenced glucose
kinetics in non-arthritic mice, decreasing C-peptide levels. This
indicate that the observed effects of ORG 37663 are not only
mediated indirectly by suppressing inflammation but might also by
directly influencing glucose kinetic pathways.
To conclude, we successfully integrated the whole body glucose
test in the CIA mice model, which enabled us to measure both
efficacy and metabolic (adverse) effects of (experimental) GCs in a
chronic in vivo inflammatory setting. Thereby, it may prove a
useful translational model for compound-induced metabolic
derangements in patients suffering from RA or other (auto)im-
mune diseases. This study showed that both inflammation and
glucocorticoids affect insulin secretion and sensitivity but this did
not lead immediately to the development of hyperglycemia and
type 2 Diabetes Mellitus. Data from this study emphasizes the
highly adaptive character of these mice and the complex network
of several integrated mechanisms underlying the development of
GC-induced and/or inflammation-induced metabolic dysfunction.
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